

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Niihara Yutaka</u> (Last) (First) (Middle) 21250 HAWTHORNE BLVD. SUITE 800 (Street) TORRANCE CA 90503 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Emmaus Life Sciences, Inc. [EMMA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <p style="text-align: center;">Chairman and CEO</p>
	3. Date of Earliest Transaction (Month/Day/Year) 10/24/2022	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common stock, \$0.001 par value	10/24/2022		P		7,500	A	\$0.22	11,898,857	D ⁽¹⁾	
Common stock, \$0.001 par value	10/25/2022		P		20,000	A	\$0.26	11,918,857	D ⁽¹⁾	
Common stock, \$0.001 par value	10/26/2022		P		11,900	A	\$0.27 ⁽²⁾	11,930,757	D ⁽¹⁾	
Common stock, \$0.001 par value	10/27/2022		P		22,500	A	\$0.27 ⁽³⁾	11,953,257	D ⁽¹⁾	
Common stock, \$0.001 par value	10/28/2022		P		7,500	A	\$0.42 ⁽⁴⁾	11,960,757	D ⁽¹⁾	
Common stock, \$0.001 par value								92,794	I	By Hope International Hospice, Inc. ⁽⁵⁾
Common stock, \$0.001 par value								63,000	I	By Soomi Niihara

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

- The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.25 to \$0.35, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) and in footnotes (3) and (4) to this Form 4.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.26 to \$0.35, inclusive.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.40 to \$0.47, inclusive.
- Hope International Hospice, Inc. is a California corporation of which Dr. Niihara and his wife are the sole shareholders and directors.

Remarks:

Yutaka Niihara, M.D., M.P.H. 10/31/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.